

# VU Research Portal

## Optimalisation of conventional therapies in inflammatory bowel disease

Seinen, M.L.

2016

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Seinen, M. L. (2016). *Optimalisation of conventional therapies in inflammatory bowel disease: Old wine in new bottles.* [, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## CONTENTS

### **PART I**

### **INTRODUCTION**

- Chapter 1** Introduction and outline of this thesis
- Chapter 2** Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts

### **PART II**

### **OPTIMALISATION OF CONVENTIONAL THERAPIES**

- Chapter 3** Routinely established skewed thiopurine metabolism leads to a striking high rate of early therapeutic failure in patients with inflammatory bowel disease
- Chapter 4** High TPMT activity as a risk factor for severe myelosuppression during thiopurine therapy
- Chapter 5** Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease
- Chapter 6** The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study
- Chapter 7** Safe use of allopurinol and low dose mercaptopurine during pregnancy in an ulcerative colitis patient
- Chapter 8** Nodular regenerative hyperplasia of the liver in IBD patients treated with allopurinol-thiopurine combination therapy
- Chapter 9** Allopurinol-thiopurine combination therapy in inflammatory bowel disease
- Chapter 10** Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and mercaptopurine therapy does not occur on the short-term during tioguanine therapy in inflammatory bowel disease treatment
- Chapter 11** Sustained clinical benefit and tolerability of methotrexate monotherapy following thiopurine therapy in patients with Crohn's disease

**PART III PHARMACODYNAMIC MONITORING**

**Chapter 12** Rac1 a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease

**Chapter 13** Rac attack; modulation of the small GTPase Rac in inflammatory bowel disease and thiopurine therapy

**PART IV DISCUSSION**

**Chapter 14** Summary, general discussion, implications for daily clinical practice and future perspectives and challenges

**Chapter 15** Dutch summary

**PART V APPENDICES**

**Appendix I** Dosing tioguanine in inflammatory bowel disease; expert based guideline for daily practice

**Appendix II** List of abbreviations

**Appendix III** Authors and affiliations

**Appendix IV** List of publications

**Appendix V** Acknowledgement/ Dankwoord

**Appendix VI** About the author